Skip to main content

8110 Gatehouse Road, Falls Church, VA 22042

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)

Translate

General Information

Age Group

Adults

Status

Recruiting

Protocol Number

NCT03834493

Background Information

The purpose of this study is to test the safety and efficacy of Pembrolizumab, also known as KEYTRUDA®, or a placebo in combination with a hormone drug (Enzalutamide) for prostate cancer

For more information go to https://clinicaltrials.gov/ct2/show/NCT03834493

Offered At

Inova Schar Cancer Institute
A department of Inova Fairfax Hospital
8081 Innovation Park Drive
Fairfax, VA 22031

Eligibility Information

  • Adult males with adenocarcinoma of the prostate without small cell histology
  • Evidence of metastatic disease
  • Additional eligibility in protocol

Ineligibility Information

  • Active autoimmune disease
  • Gastrointestinal disorders affecting absorption
  • Active central nervous system metastases
  • Additional ineligibility in protocol